FBXO30

Across TCGA pan-cancer cohorts, FBXO30 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO30 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher FBXO30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO30 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

COAD, READ, and PRAD are the cancer types where FBXO30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.212	0.807	<.001	32	view →
READ	DFS	Median	All	0.112	0.845	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	1.000	0.577	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO30–COAD (OS)

Open the COAD breakdown →